TRITON
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
- NCT06008093 ↗
- Active not recruiting
- AstraZeneca
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase IIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab; Tremelimumab; Pemetrexed; Pembrolizumab; Carboplatin; Cisplatin
- Arms
- Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy · Experimental
- Arm B: Pembrolizumab + Platinum-based Chemotherapy · Experimental
- Enrollment
- 103
- Primary outcomes
- Progression-free survival (PFS) in randomized participants
- PFS at 6 months
- PFS at 12 months
- Sponsor
- AstraZeneca
- Start
- Apr 4, 2024
- Primary completion
- Oct 23, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06008093 · updated Jul 2, 2026
Publications
linked from the registry- Skoulidis F, Borghaei H, Garon EB, Leal TA, Kaufman J, Liu SV, Nadler E, Patel SP, Peters S, Ricciuti B, Gautam A, Emeribe U, Luciani-Silverman L, Heymach JV. Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study. Ther Adv Med Oncol. 2025 Nov 6;17:17588359251386611. doi: 10.1177/17588359251386611. eCollection 2025. PubMed 41209621